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Outcomes in Adults With Acute Pulmonary Embolism Who Are Discharged From Emergency Departments: The Cardiovascular Research Network Venous Thromboembolism Study
Patients with acute pulmonary embolism (PE) have conventionally been hospitalized for their initial management and initiation of anticoagulant treatment.
1 A clinical trial 2 found that patients with PE who were considered at low risk by the PE Severity Index could be safely treated as outpatients. 3 However, it is unclear how often outpatient PE treatment occurs in real-world settings or whether outcomes are as favorable as in the clinical trial. Our study describes the short-term rates of death and hospital admission for patients with acute PE who were discharged from emergency department (ED) settings. December 31, 2010 . We restricted the analysis to patients who were discharged from EDs with an anticoagulant prescription within 7 days. Exclusion criteria were less than 12 months of continuous pharmacy benefits, prior venous thromboembolism diagnoses, or outpatient anticoagulant prescriptions within 4 years. Anticoagulants included warfarin sodium, low-molecularweight heparins, and fondaparinux sodium (because targetspecific oral anticoagulants were not yet approved for use in PE). Data regarding patient demographics, medication use, and ICD-9 diagnoses were obtained from electronic databases. Primary outcomes for this analysis included hospital admission within 30 days and death within 90 days of the index ED encounter. We used descriptive statistics to report outcome rates. This study was approved by institutional review boards of the participating sites (Kaiser Permanente Northern California, Kaiser Permanente Colorado, Marshfield Clinic Research Foundation, and Geisinger Health System) and a waiver of informed consent was obtained owing to the nature of the study.
Results | Of 5927 patients with a primary diagnosis of PE, 494 (8.3%) were discharged from ED settings. The proportion of EDdischarged patients with PE increased over time, from 37 of 657 (5.6%) in 2004 to 110 of 994 (11.1%) in 2010 (P <.001 for trend). Characteristics of ED-discharged patients are presented in the Table. 4 Within 30 days of discharge from the ED, 92 of the 494 patients with PE (18.6%) had another visit to the ED and 39 (7.9%) were hospitalized. Eleven patients (2.2%) had a primary diagnosis of hemorrhage during a subsequent visit to the ED or hospital within 30 days. Mortality was low-none died within 7 days and 2 died (0.4%) within 90 days.
Discussion | Patients with acute PE who were discharged from ED settings in 4 geographically diverse health care delivery systems had mortality rates comparable with outcomes observed in a clinical trial 3 that examined outpatient management of PE. Although still representing relatively few patients with PE, the proportion of discharges from ED settings nearly doubled during the 7-year study. Shifting appropriate patients to outpatient treatment may have benefits in terms of improved quality of life, enhanced physical and social functioning, and reduced costs of medical care. 5 We note that at least 23.4% of the patients in our study would not have been eligible for outpatient treatment in the clinical trial because they had a higher PE Severity Index risk class.
3
Limitations to our study include identification of PEs using ICD-9 codes and pharmacy data alone, the lack of detailed physiologic data required to calculate a full PE severity risk class, and the inability to determine specific reasons for patient disposition plans. 
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Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism: Insights From the NCDR PINNACLE Registry
In patients with atrial fibrillation (AF) who are at risk for thromboembolism, anticoagulation therapy with warfarin or the newer novel anticoagulants reduces morbidity and mortality.
1,2
Because oral anticoagulant use carries a risk of bleeding, the drugs are not recommended in patients with AF who are at a particularly low risk for stroke. Specifically, previous AF guidelines recommend against the use of oral anticoagulation in patients younger than 60 years without heart disease or other known risk factors for thromboembolism, 3 and more recently updated guidelines do not recommend the use of oral anticoagulation in patients with AF without any established risk factor for stroke. 4 We sought to examine the prevalence of oral anticoagulant prescription that does not adhere to the guidelines in young and healthy patients with AF who were at the lowest risk for thromboembolism, as well as the clinical predictors of this practice. Results | In the cohort of patients with a CHADS 2 score of 0 and the cohort of those with a CHA 2 DS 2 -VASc score of 0, a total of 2561 (23.3%) and 1787 (26.6%) patients with AF, respectively, were prescribed an oral anticoagulant. Demographics and clinical characteristics of patients in each cohort stratified by prescription of oral anticoagulants are shown in the Table. In both the cohort of patients with a CHADS 2 score of 0 and the cohort of those with a CHA 2 DS 2 -VASc score of 0, patients with AF who were prescribed oral anticoagulants were older and more frequently insured by Medicare or were uninsured. Patients in both cohorts who were prescribed oral anticoagulation had a higher body mass index, and a greater proportion of patients received anticoagulation than not in the Northeast and West. Patients prescribed oral anticoagulants were less likely to have paroxysmal AF or to be current smokers. In only the cohort of patients with a CHADS 2 score of 0, patients who were prescribed oral anticoagulants were more likely to be male and have dyslipidemia. In multivari-
